US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
ATE157864T1
(de)
|
1991-12-18 |
1997-09-15 |
Warner Lambert Co |
Verfahren für die herstellung einer festen dispersion
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
WO1994008561A1
(en)
*
|
1992-10-14 |
1994-04-28 |
Nippon Shinyaku Co., Ltd. |
Crystalline condition dislocating method
|
US5811547A
(en)
*
|
1992-10-14 |
1998-09-22 |
Nippon Shinyaju Co., Ltd. |
Method for inducing crystalline state transition in medicinal substance
|
EP0665010B1
(de)
*
|
1992-10-16 |
2002-09-11 |
Nippon Shinyaku Company, Limited |
Verfahren zur herstellung von wachsmatrizes
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
IL110014A
(en)
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US6312726B1
(en)
*
|
1993-08-20 |
2001-11-06 |
Nippon Shinyaku Co., Ltd. |
Gastric remaining preparation, swollen molding, and production process
|
GB2281697A
(en)
*
|
1993-09-14 |
1995-03-15 |
Euro Celtique Sa |
Laxative compositions in capsules
|
US5688510A
(en)
*
|
1993-11-18 |
1997-11-18 |
Nippon Shinyaku Co. Ltd. |
Process for producing stable medicinal composition, and pharmaceutical preparation
|
DE19509807A1
(de)
*
|
1995-03-21 |
1996-09-26 |
Basf Ag |
Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
EP0797987B1
(de)
*
|
1994-12-19 |
2003-10-15 |
Daiichi Pharmaceutical Co., Ltd. |
Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
|
BE1009856A5
(fr)
*
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
PT784974E
(pt)
*
|
1995-07-26 |
2003-09-30 |
Kyowa Hakko Kogyo Kk |
Preparacao de derivados de xantina numa dispersao solida
|
TW487582B
(en)
|
1995-08-11 |
2002-05-21 |
Nissan Chemical Ind Ltd |
Method for converting sparingly water-soluble medical substance to amorphous state
|
CZ293841B6
(cs)
*
|
1996-05-20 |
2004-08-18 |
Janssenápharmaceuticaán@Áv |
Částice s obsahem itrakonazolu
|
US6139872A
(en)
*
|
1996-08-14 |
2000-10-31 |
Henkel Corporation |
Method of producing a vitamin product
|
JPH10114682A
(ja)
*
|
1996-10-11 |
1998-05-06 |
Shimizu Kagaku Kk |
グルコマンナン配合持効性内服用薬剤
|
US5955475A
(en)
*
|
1997-06-30 |
1999-09-21 |
Endo Pharmaceuticals Inc. |
Process for manufacturing paroxetine solid dispersions
|
EP1745774A3
(de)
|
1997-08-11 |
2007-04-11 |
Pfizer Products Inc. |
Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
|
ES2287971T3
(es)
|
1997-08-11 |
2007-12-16 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
|
HN1998000115A
(es)
*
|
1997-08-21 |
1999-06-02 |
Warner Lambert Co |
Formas de dosificación farmacéuticas sólidas
|
US6013280A
(en)
*
|
1997-10-07 |
2000-01-11 |
Fuisz Technologies Ltd. |
Immediate release dosage forms containing microspheres
|
AU8621398A
(en)
*
|
1998-01-12 |
1999-07-26 |
Buhler Ag |
Method and device for capsulating active ingredients
|
IE980115A1
(en)
*
|
1998-02-16 |
2000-02-09 |
Biovail Internat Ltd |
Solubilizing delivery systems and method of manufacture
|
DE29923766U1
(de)
*
|
1998-05-27 |
2001-06-07 |
Euro Celtique Sa |
Wirkstoffapplikationssystem umfassend einen hochverdichteten festen Arzneimittelvorrat
|
DE19842753A1
(de)
|
1998-09-18 |
2000-03-23 |
Bayer Ag |
Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
|
DE19842914A1
(de)
*
|
1998-09-18 |
2000-03-23 |
Basf Ag |
Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
|
US6350786B1
(en)
†
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
AP1769A
(en)
*
|
1998-12-16 |
2007-08-22 |
Aventisub Ii Inc |
Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same.
|
US6455526B1
(en)
|
1998-12-16 |
2002-09-24 |
Aventis Pharmaceuticals, Inc. |
Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
|
ES2306646T3
(es)
|
1999-02-09 |
2008-11-16 |
Pfizer Products Inc. |
Composiciones de farmacos basicos con biodisponibilidad incrementada.
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
ATE400252T1
(de)
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
Pharmazeutische feste dispersionen
|
JP2000281561A
(ja)
*
|
1999-03-26 |
2000-10-10 |
Ajinomoto Co Inc |
新規溶媒法固体分散体製剤
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US7300667B1
(en)
|
1999-05-27 |
2007-11-27 |
Euro-Celtique, S.A. |
Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
|
US7297344B1
(en)
|
1999-05-27 |
2007-11-20 |
Euro-Celtique, S.A. |
Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
|
ATE340561T1
(de)
|
1999-05-27 |
2006-10-15 |
Euro Celtique Sa |
Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen
|
DE19945982A1
(de)
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
DE19949897A1
(de)
*
|
1999-10-15 |
2001-04-19 |
Rainer Rogasch |
Formkörper und Verfahren zu dessen Herstellung
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
CN102716101A
(zh)
|
1999-10-29 |
2012-10-10 |
欧罗赛铁克股份有限公司 |
控释氢可酮制剂
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
WO2001034119A2
(en)
|
1999-11-12 |
2001-05-17 |
Abbott Laboratories |
Inhibitors of crystallization in a solid dispersion
|
AP2002002552A0
(en)
|
1999-12-23 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical compositions providing enhanced drug concentrations.
|
CA2403380A1
(en)
*
|
2000-03-21 |
2002-09-19 |
Nippon Shinyaku Co., Ltd. |
Sustained release oral preparations
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
DE10031044A1
(de)
|
2000-06-26 |
2002-01-03 |
Bayer Ag |
Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
|
JP3563070B2
(ja)
*
|
2000-07-17 |
2004-09-08 |
山之内製薬株式会社 |
経口吸収改善医薬組成物
|
US7115279B2
(en)
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
JP4997683B2
(ja)
*
|
2000-09-25 |
2012-08-08 |
日本新薬株式会社 |
医薬固体分散体の製法
|
EP2283829A1
(de)
|
2000-10-30 |
2011-02-16 |
Euro-Celtique S.A. |
Hydrocodon-Formulierungen mit gesteuerter Freisetzung
|
ITMI20010141A1
(it)
*
|
2001-01-26 |
2002-07-26 |
Giuliani Spa |
Procedimento per la preparazione di composizioni farmaceutiche o dietetiche per la veicolazione nell'intestino di sostanze labili
|
RU2003128971A
(ru)
*
|
2001-02-27 |
2005-03-10 |
Астразенека Аб (Se) |
Фармацевтический препарат
|
GB0104752D0
(en)
*
|
2001-02-27 |
2001-04-18 |
Astrazeneca Ab |
Pharmaceutical compositions
|
US6465014B1
(en)
*
|
2001-03-21 |
2002-10-15 |
Isp Investments Inc. |
pH-dependent sustained release, drug-delivery composition
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
MXPA03011933A
(es)
*
|
2001-06-22 |
2004-03-26 |
Pfizer Prod Inc |
Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados.
|
JP2004534811A
(ja)
*
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
ポリマーと薬剤の集合体を含む医薬組成物
|
BR0210520A
(pt)
|
2001-06-22 |
2004-06-22 |
Pfizer Prod Inc |
Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
|
EP1404300B1
(de)
*
|
2001-06-22 |
2009-09-30 |
Pfizer Products Inc. |
Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
|
EP1269994A3
(de)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
SE0103424D0
(sv)
*
|
2001-10-15 |
2001-10-15 |
Astrazeneca Ab |
Pharmaceutical formulation
|
US7491407B2
(en)
*
|
2001-10-31 |
2009-02-17 |
North Carolina State University |
Fiber-based nano drug delivery systems (NDDS)
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
EP1920766B1
(de)
|
2002-02-01 |
2017-08-23 |
Bend Research, Inc |
Pharmazeutische Zusammensetzungen amorpher Dispersionen von Wirkstoffen und lipophiler mikrophasenbildender Materialien
|
DE60322665D1
(de)
|
2002-02-01 |
2008-09-18 |
Pfizer Prod Inc |
Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
|
RU2278659C9
(ru)
*
|
2002-02-01 |
2007-02-20 |
Пфайзер Продактс Инк. |
Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
|
US20030204180A1
(en)
*
|
2002-04-30 |
2003-10-30 |
Kimberly-Clark Worldwide, Inc. |
Temperature responsive delivery systems
|
ATE442130T1
(de)
|
2002-08-12 |
2009-09-15 |
Bend Res Inc |
Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
|
WO2004056358A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
|
US7423004B2
(en)
*
|
2003-01-31 |
2008-09-09 |
Smithkline Beecham Corporation |
Solid dispersion compositions
|
CA2509958A1
(en)
*
|
2003-02-03 |
2004-08-19 |
Novartis Ag |
Pharmaceutical formulation
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
EP1696887A1
(de)
*
|
2003-11-14 |
2006-09-06 |
Pfizer Products Inc. |
Feste amorphe dispersionen eines mtp-hemmers zur behandlung von fettsucht
|
BRPI0417492A
(pt)
*
|
2003-12-09 |
2007-05-29 |
Pfizer |
composições compreendendo um inibidor de protease de hiv
|
AU2005214159A1
(en)
|
2004-02-04 |
2005-09-01 |
Pfizer Products Inc. |
Substituted quinoline compounds
|
US20050238721A1
(en)
*
|
2004-04-07 |
2005-10-27 |
Acquarulo Lawrence A Jr |
One step compounding extrusion of drug filled polymers
|
US20070237823A1
(en)
*
|
2004-05-04 |
2007-10-11 |
Thomas Bock |
Solid Pharmaceutical Form Comprising and Ltb4 Antagonist
|
GEP20094723B
(en)
|
2004-05-25 |
2009-07-10 |
Pfizer Prod Inc |
Tetraazabenzo [e] azulene derivatives and analogs thereof
|
CA2568007A1
(en)
*
|
2004-05-28 |
2005-12-08 |
Pfizer Products Inc. |
Pharmaceutical compositions with enhanced performance
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
DK1848430T3
(da)
|
2004-12-31 |
2017-11-06 |
Dr Reddys Laboratories Ltd |
Nye benzylamin-derivativer som cetp-inhibitors
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
EP2548894A1
(de)
|
2005-02-03 |
2013-01-23 |
Bend Research, Inc. |
Pharmazeutische Zusammensetzungen mit erhöhter Leistung
|
EP1690528A1
(de)
*
|
2005-02-11 |
2006-08-16 |
Abbott GmbH & Co. KG |
Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
|
BRPI0614197B8
(pt)
*
|
2005-08-02 |
2021-05-25 |
Drossapharm Ag |
composição farmaceuticamente eficaz em uma forma farmacêutica para administração peroral contendo pelo menos um dos ingredientes ativos indometacina e acemetacina, formas de administração, e, uso da composição
|
EP1933852B1
(de)
*
|
2005-09-27 |
2018-12-19 |
TissueTech, Inc. |
Amnion-zubereitungen und gereinigte zusammensetzungen und anwendungsverfahren
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
JP5334588B2
(ja)
|
2005-11-28 |
2013-11-06 |
マリナス ファーマシューティカルズ |
ガナキソロン製剤、およびその作製方法、およびその使用
|
EP1832281A1
(de)
*
|
2006-03-10 |
2007-09-12 |
Abbott GmbH & Co. KG |
Verfahren zur Herstellung einer Feststoffdispersion eines aktiven Wirkstoffes
|
ATE510538T1
(de)
|
2006-08-11 |
2011-06-15 |
Univ Johns Hopkins |
Zusammensetzungen und verfahren für nervenschutz
|
NZ601278A
(en)
|
2006-09-22 |
2013-09-27 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US7607596B1
(en)
|
2007-03-07 |
2009-10-27 |
Exxpharma, LLC |
Process for enhancing the solubility of poorly soluble drugs
|
WO2008135855A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
|
US8309129B2
(en)
|
2007-05-03 |
2012-11-13 |
Bend Research, Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
EP2162120B1
(de)
|
2007-06-04 |
2016-05-04 |
Bend Research, Inc |
Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
|
US9545384B2
(en)
|
2007-06-04 |
2017-01-17 |
Bend Research, Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
|
NZ582772A
(en)
|
2007-07-17 |
2012-06-29 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
US8183381B2
(en)
*
|
2007-07-19 |
2012-05-22 |
Metabolex Inc. |
N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
|
US8486423B2
(en)
|
2007-08-21 |
2013-07-16 |
Board Of Regents, The University Of Texas System |
Thermo-kinetic mixing for pharmaceutical applications
|
EP2200607A4
(de)
|
2007-09-10 |
2012-02-22 |
Calcimedica Inc |
Verbindungen als modulatoren von intrazellulärem calcium
|
US20100240711A1
(en)
*
|
2007-09-21 |
2010-09-23 |
Shionogi & Co., Ltd. |
Solid preparation comprising npyy5 receptor antagonist
|
PL2200588T3
(pl)
|
2007-09-25 |
2019-09-30 |
Solubest Ltd. |
Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
|
WO2009053635A1
(fr)
*
|
2007-10-11 |
2009-04-30 |
L'oreal |
Composition cosmetique structuree
|
FR2922100B1
(fr)
*
|
2007-10-11 |
2009-12-11 |
Oreal |
Procede de preparation de particules semi-solides a interet cosmetique
|
WO2009073216A1
(en)
|
2007-12-06 |
2009-06-11 |
Bend Research, Inc. |
Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
|
WO2009073215A1
(en)
|
2007-12-06 |
2009-06-11 |
Bend Research, Inc. |
Pharmaceutical compositions comprising nanoparticles and a resuspending material
|
WO2009085637A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Url Pharma, Inc. |
Amorphous metaxalone and amorphous dispersions thereof
|
US20100048913A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
MX2010010562A
(es)
*
|
2008-03-31 |
2010-12-07 |
Metabolex Inc |
Compuestos de oximetilen-arilo y uso de los mismos.
|
BRPI0917719A2
(pt)
|
2008-08-27 |
2019-11-19 |
Calcimedica Inc |
compostos que modulam cálcio intracelular
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
BRPI1008745A2
(pt)
|
2009-02-05 |
2019-09-17 |
Tokai Pharmaceuticals Inc |
pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
|
EA031116B1
(ru)
|
2009-04-03 |
2018-11-30 |
Ф. Хоффманн-Ля Рош Аг |
КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
|
WO2010124296A2
(en)
|
2009-04-24 |
2010-10-28 |
Tissuetech, Inc. |
Compositions containing hc•ha complex and methods of use thereof
|
HUE048542T2
(hu)
|
2009-06-16 |
2020-08-28 |
Pfizer |
Apixaban adagolási formái
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
ES2497566T3
(es)
*
|
2009-10-01 |
2014-09-23 |
Cymabay Therapeutics, Inc. |
Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
MX2012005284A
(es)
|
2009-11-06 |
2012-06-28 |
Plexxikon Inc |
Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello.
|
CN102821754B
(zh)
*
|
2010-03-26 |
2014-06-18 |
陶氏环球技术有限责任公司 |
多层熔融挤出膜
|
CN103153580A
(zh)
*
|
2010-03-26 |
2013-06-12 |
陶氏环球技术有限责任公司 |
制备熔体挤出的膜的方法和熔体挤出的膜
|
KR20130080004A
(ko)
*
|
2010-03-26 |
2013-07-11 |
다우 글로벌 테크놀로지스 엘엘씨 |
용융-압출된 필름
|
EP2558866B1
(de)
|
2010-04-15 |
2016-08-17 |
Tracon Pharmaceuticals, Inc. |
Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
|
EP2563776B1
(de)
|
2010-04-27 |
2016-06-08 |
Calcimedica, Inc. |
Verbindungen als modulatoren von intrazellulärem calcium
|
US8754219B2
(en)
|
2010-04-27 |
2014-06-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
EP2571860A1
(de)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl-benzoylamide
|
CA3007787C
(en)
|
2010-06-03 |
2020-03-10 |
Pharmacyclics Llc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
EP2585048B1
(de)
*
|
2010-06-23 |
2018-04-11 |
CymaBay Therapeutics, Inc. |
Zusammensetzungen von 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidin
|
ES2792800T3
(es)
|
2010-07-02 |
2020-11-12 |
Procter & Gamble |
Métodos de suministro de una sustancia activa para el cuidado de la salud mediante la administración de artículos para el cuidado de la salud personal que comprenden un filamento
|
MX337711B
(es)
|
2010-08-27 |
2016-03-15 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
PT2672967T
(pt)
|
2011-02-07 |
2018-12-07 |
Plexxikon Inc |
Compostos e métodos de modulação da quinase e suas indicações
|
CA2824639A1
(en)
|
2011-02-17 |
2012-08-23 |
Ashish Chatterji |
A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
DE102011015370A1
(de)
*
|
2011-03-29 |
2012-10-04 |
Emodys Gmbh |
Matrix für eine orale Darreichungsform, Verfahren zu deren Herstellung sowie Verwendung derselben
|
US9526770B2
(en)
|
2011-04-28 |
2016-12-27 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
CA2837878A1
(en)
|
2011-06-10 |
2012-12-13 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
JP5964965B2
(ja)
|
2011-08-18 |
2016-08-03 |
ドクター レディズ ラボラトリーズ リミテッド |
コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
|
US9492423B2
(en)
|
2011-09-13 |
2016-11-15 |
Pharmacyclics Llc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
WO2013046045A1
(en)
|
2011-09-27 |
2013-04-04 |
Dr. Reddy's Laboratories, Ltd. |
5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
EP3698782A1
(de)
|
2012-01-06 |
2020-08-26 |
Lundbeck La Jolla Research Center, Inc. |
Carbamatverbindungen zur verwendung in therapie
|
IN2012DE00674A
(de)
|
2012-03-07 |
2015-08-21 |
Nat Inst Of Pharmaceutical Education And Res Niper |
|
CN104334557A
(zh)
|
2012-04-06 |
2015-02-04 |
辉瑞公司 |
二酰基甘油酰基转移酶2抑制剂
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
MY187999A
(en)
|
2012-06-04 |
2021-11-08 |
Pharmacyclics Llc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
JP2015528001A
(ja)
|
2012-07-11 |
2015-09-24 |
ティッシュテック,インク. |
Hc−ha/ptx3複合体を含む組成物およびその使用方法
|
CA2885828C
(en)
|
2012-09-28 |
2021-04-27 |
University Of Washington Through Its Center For Commercialization |
Ureido-thiophenyl derivatives, compositions thereof and methods for preventing, treating and/or protecting against sensory hair cell death
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR102191562B1
(ko)
|
2012-11-07 |
2020-12-15 |
에스케이바이오팜 주식회사 |
난용성 약물의 고체분산체 및 이의 제조방법
|
EP2919765A2
(de)
|
2012-11-19 |
2015-09-23 |
Dr. Reddy's Laboratories Ltd. |
Pharmazeutische cetp-inhibitorzusammensetzungen
|
JP6150518B2
(ja)
|
2012-12-27 |
2017-06-21 |
花王株式会社 |
ポリフェノール組成物の製造方法
|
WO2014128564A2
(en)
|
2013-02-21 |
2014-08-28 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical compositions of cetp inhibitors
|
SG11201507093WA
(en)
|
2013-03-14 |
2015-10-29 |
Univ Maryland Baltimore Office Of Technology Transfer |
Androgen receptor down-regulating agents and uses thereof
|
CN105636594A
(zh)
|
2013-08-12 |
2016-06-01 |
托凯药业股份有限公司 |
使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
|
EP2837391B1
(de)
|
2013-08-12 |
2017-05-10 |
Shin-Etsu Chemical Co., Ltd. |
Hypromellose-Acetat-Succinat zur Verwendung als Heißschmelzextrusionsträger, Heißschmelzextrusionszusammensetzung und Verfahren zur Herstellung eines Heißschmelzextrudats
|
WO2015034889A2
(en)
|
2013-09-04 |
2015-03-12 |
Zzyzx Polymers LLC |
Methods for increasing throughput rates of solid-state extrusion devices
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
WO2015054595A1
(en)
*
|
2013-10-12 |
2015-04-16 |
Zzyzx Polymers LLC |
Fabricating drug delivery systems
|
BR112016012728A2
(pt)
|
2013-12-05 |
2020-08-11 |
Pharmacyclics Llc |
compostos inibidores de tirosina quinase de bruton, composição farmacêutica os compreendendo e uso dos mesmos
|
HUE049323T2
(hu)
|
2014-02-10 |
2020-09-28 |
Respivant Sciences Gmbh |
Hízósejt-stabilizálók tüdõbetegség kezelésére
|
PT3104853T
(pt)
|
2014-02-10 |
2020-01-14 |
Respivant Sciences Gmbh |
Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
|
EP3119757B1
(de)
|
2014-03-17 |
2018-05-16 |
Pfizer Inc |
Diacylglycerol-acyltransferase-2-inhibitoren zur behandlung von stoffwechselerkrankungen und damit assoziierten leiden
|
CN106232144B
(zh)
|
2014-03-18 |
2019-12-06 |
武田药品工业株式会社 |
固体分散体
|
WO2015164213A1
(en)
|
2014-04-23 |
2015-10-29 |
The Research Foundation For The State University Of New York |
A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
CN106793821B
(zh)
|
2014-08-29 |
2021-05-07 |
花王株式会社 |
含有难溶性多酚类的固体分散体的制造方法
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
AU2015317358A1
(en)
*
|
2014-09-19 |
2017-04-27 |
Board Of Regents, The University Of Texas System |
Methods of preparing extrudates
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
US10399994B2
(en)
|
2015-02-06 |
2019-09-03 |
University Of Washington |
Compounds and methods for preventing or treating sensory hair cell death
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
EA039121B1
(ru)
|
2015-02-27 |
2021-12-07 |
Куртана Фармасьютикалс, Инк. |
ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
|
TW202315634A
(zh)
|
2015-03-03 |
2023-04-16 |
美商製藥公司 |
布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物
|
MA41828A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
|
MA41827A
(fr)
|
2015-03-27 |
2018-01-30 |
Pharmacyclics Llc |
Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
|
CA2984480A1
(en)
|
2015-05-11 |
2016-11-17 |
Abide Therapeutics, Inc. |
Methods of treating inflammation or neuropathic pain
|
CN107847526A
(zh)
|
2015-05-20 |
2018-03-27 |
组织技术公司 |
用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
|
AU2016267685A1
(en)
|
2015-05-28 |
2017-12-07 |
Dr. Reddy's Laboratories Ltd. |
Oral composition of celecoxib for treatment of pain
|
US10265296B2
(en)
|
2015-08-07 |
2019-04-23 |
Respivant Sciences Gmbh |
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
|
EP3331522A1
(de)
|
2015-08-07 |
2018-06-13 |
Patara Pharma LLC |
Verfahren zur behandlung von mastzellbedingten erkrankungen mit mastzellstabilisatoren
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
ES2908479T3
(es)
|
2015-08-26 |
2022-04-29 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
|
WO2017040617A1
(en)
|
2015-08-31 |
2017-03-09 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
ES2952064T3
(es)
|
2015-12-16 |
2023-10-26 |
Walter & Eliza Hall Inst Medical Res |
Inhibición de la proteína SH2 inducida por citocinas en células NK
|
EP3405178A1
(de)
|
2016-01-19 |
2018-11-28 |
Janssen Pharmaceutica NV |
Formulierungen/zusammensetzungen mit einem btk-inhibitoren
|
EA201891440A1
(ru)
|
2016-01-19 |
2018-12-28 |
Янссен Фармацевтика Нв |
Составы/композиции, содержащие ингибитор btk
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
US10851123B2
(en)
|
2016-02-23 |
2020-12-01 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
JP7049683B2
(ja)
|
2016-04-04 |
2022-04-07 |
シノピア バイオサイエンシーズ,インク. |
トラピジルを使用する錐体外路症候群の処置
|
US11883381B2
(en)
|
2016-05-12 |
2024-01-30 |
The Regents Of The University Of Michigan |
ASH1L inhibitors and methods of treatment therewith
|
US11045550B2
(en)
|
2016-05-13 |
2021-06-29 |
Merck Patent Gmbh |
Use of an amino sugar as plasticizer
|
KR20210145306A
(ko)
|
2016-05-13 |
2021-12-01 |
메르크 파텐트 게엠베하 |
용융 압출 적용을 위한 중합체의 입자 크기 및 분포
|
WO2017205534A1
(en)
|
2016-05-25 |
2017-11-30 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
RU2018145364A
(ru)
|
2016-06-27 |
2020-07-28 |
Ачиллион Фармасьютикалс, Инк. |
Хиназолиновые и индольные соединения для лечения медицинских нарушений
|
DK3484862T3
(da)
|
2016-07-18 |
2021-11-08 |
Arthrosi Therapeutics Inc |
Forbindelser, sammensætninger og fremgangsmåder til behandling eller forebyggelse af et symptom, der er forbundet med gigt eller hyperurikæmi
|
KR20190035752A
(ko)
|
2016-08-03 |
2019-04-03 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
염증성 위장 질환 또는 위장 상태를 치료하기 위한 옥시메틸렌 아릴 화합물
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
KR102468670B1
(ko)
|
2016-08-26 |
2022-11-17 |
커타나 파마슈티칼스, 인크. |
Olig2 활성의 억제
|
AU2017321495A1
(en)
|
2016-08-31 |
2019-03-21 |
Respivant Sciences Gmbh |
Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
|
WO2018067341A1
(en)
|
2016-10-07 |
2018-04-12 |
Patara Pharma, LLC |
Cromolyn compositions for treatment of pulmonary fibrosis
|
JP2019534293A
(ja)
|
2016-11-07 |
2019-11-28 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
ポリビニルアルコールを基にする制御放出錠剤およびその製造
|
WO2018083113A1
(en)
|
2016-11-07 |
2018-05-11 |
Merck Patent Gmbh |
Instant release capsule based on hot melt extruded polyvinyl alcohol
|
MX2019005304A
(es)
|
2016-11-07 |
2019-08-12 |
Merck Patent Gmbh |
Pastilla de liberacion no abrupta de una dosis inducida por alcohol basada en alcohol polivinilico.
|
ES2900016T3
(es)
|
2016-11-16 |
2022-03-15 |
H Lundbeck As |
Una forma cristalina de un inhibidor de MAGL
|
JP2020500176A
(ja)
|
2016-11-16 |
2020-01-09 |
ルンドベック ラ ホーヤ リサーチ センター,インク. |
医薬製剤
|
US11312713B2
(en)
|
2017-03-10 |
2022-04-26 |
Pfizer Inc. |
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
|
CN109320428A
(zh)
*
|
2017-08-01 |
2019-02-12 |
浙江普利药业有限公司 |
一种马来酸曲美布汀晶型及其制备方法
|
AU2018325267B2
(en)
|
2017-09-01 |
2023-03-30 |
University Of Washington |
Crystalline forms of compounds for preventing or treating sensory hair cell death
|
EP3706867A4
(de)
|
2017-11-07 |
2021-08-11 |
The Regents Of The University Of Michigan |
Therapeutische kombination zur behandlung von cerebellärer ataxie
|
US11110177B2
(en)
|
2017-11-10 |
2021-09-07 |
The Regents Of The University Of Michigan |
ASH1L degraders and methods of treatment therewith
|
EP3720439A4
(de)
|
2017-12-07 |
2021-09-08 |
The Regents Of The University Of Michigan |
Inhibitoren der nsd-familie und behandlungsverfahren damit
|
US11685722B2
(en)
|
2018-02-28 |
2023-06-27 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
US11319302B2
(en)
|
2018-06-07 |
2022-05-03 |
The Regents Of The University Of Michigan |
PRC1 inhibitors and methods of treatment therewith
|
TW202019887A
(zh)
|
2018-07-27 |
2020-06-01 |
美商同心止痛劑股份有限公司 |
酚系trpv1促效劑之聚乙二醇化前藥
|
EP3841086A4
(de)
|
2018-08-20 |
2022-07-27 |
Achillion Pharmaceuticals, Inc. |
Pharmazeutische zusammensetzungen zur behandlung von medizinischen störungen im zusammenhang mit komplementfaktor d
|
WO2020046466A1
(en)
|
2018-08-29 |
2020-03-05 |
Myos Rens Technology, Inc. |
Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
|
TWI718644B
(zh)
|
2018-08-31 |
2021-02-11 |
美商輝瑞股份有限公司 |
用於治療nash/nafld和相關疾病之組合
|
US20200108102A1
(en)
|
2018-10-03 |
2020-04-09 |
Myos Rens Technology Inc. |
Spray dried follistatin product
|
CN113365617A
(zh)
|
2018-10-16 |
2021-09-07 |
乔治亚州立大学研究基金会股份有限公司 |
用于医学疾病治疗的一氧化碳前药
|
US10925904B2
(en)
|
2018-11-06 |
2021-02-23 |
Myos Rens Technology, Inc. |
Methods and compositions for improving skeletal muscle protein fractional synthetic rate
|
BR112021011578A2
(pt)
|
2018-12-31 |
2021-08-31 |
Biomea Fusion, Llc |
Inibidores irreversíveis de interação menina-mll
|
US11833186B2
(en)
|
2019-02-01 |
2023-12-05 |
Myos Corp. |
Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
|
EP3937938A1
(de)
|
2019-03-15 |
2022-01-19 |
Unicycive Therapeutics Inc. |
Nicorandilderivate
|
US20220175677A1
(en)
*
|
2019-04-08 |
2022-06-09 |
Cosci Med-Tech Co., Ltd. |
Methods of improving pharmaceutical substance solubilization and products thereof
|
CN114007697A
(zh)
|
2019-04-19 |
2022-02-01 |
辉瑞公司 |
用于治疗pah的抗增殖剂
|
CN113874019A
(zh)
|
2019-05-20 |
2021-12-31 |
辉瑞大药厂 |
用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
|
CA3144848C
(en)
|
2019-06-28 |
2023-11-21 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
JP2021134211A
(ja)
|
2020-02-24 |
2021-09-13 |
ファイザー・インク |
Nafld/nashおよび関連疾患の処置のための組合せ
|
JP2023523219A
(ja)
|
2020-04-21 |
2023-06-02 |
ハー・ルンドベック・アクチエゼルスカベット |
モノアシルグリセロールリパーゼ阻害剤の合成
|
EP4161927A1
(de)
|
2020-06-09 |
2023-04-12 |
Pfizer Inc. |
Spiroverbindungen als melanocortin-4-rezeptorantagonisten und verwendungen davon
|
JP2023533982A
(ja)
|
2020-07-10 |
2023-08-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Gas41阻害剤及びその使用方法
|
CA3202151A1
(en)
|
2020-12-16 |
2022-06-23 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin-mll interaction
|
CA3204457A1
(en)
|
2021-01-06 |
2022-07-14 |
Ben SESSA |
Mdma in the treatment of alcohol use disorder
|
WO2022238507A1
(en)
|
2021-05-11 |
2022-11-17 |
Awakn Ls Europe Holdings Limited |
Therapeutic aminoindane compounds and compositions
|
CA3221280A1
(en)
|
2021-06-03 |
2022-12-08 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
AU2022325861A1
(en)
|
2021-08-11 |
2024-02-29 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
AU2022331496A1
(en)
|
2021-08-20 |
2024-02-29 |
Biomea Fusion, Inc. |
Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
US11945785B2
(en)
|
2021-12-30 |
2024-04-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of FLT3
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|
US20240010649A1
(en)
|
2022-07-06 |
2024-01-11 |
Oppilan Pharma Limited |
Crystalline forms of an s1p receptor modulator
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|